• Forecasts significant revenue and EBITDA growth for 1HFY25
• Organic revenue growth of ~19% and organic EBITDA growth of ~85%
• Acquisitions of Teknocorp and Amentco contribute to performance

Austco Healthcare Limited (ASX: AHC) has provided a trading update for the first half of FY25, ending 31 December 2024. The company anticipates continued strong performance, with significant revenue and EBITDA growth compared to the prior corresponding period. Austco Healthcare forecasts revenue of $35.8 million to $36.9 million, up from $22.8 million in 1HFY24, representing a mid-point growth of approximately 59%. EBITDA is forecast to be $4.5 million to $5.1 million, up from $2.1 million in 1HFY24, a mid-point growth of around 129%. The strong growth reflects the successful execution of Austco Healthcare's strategy, which combines organic revenue growth of approximately 19% and organic EBITDA growth of around 85%, together with contributions from the recent acquisitions of Teknocorp (November 2023) and Amentco (May 2024). These acquisitions are forecast to contribute between $11.8 million to $12.2 million in revenue and $1.6 million to $1.7 million in EBITDA for 1HFY25. The company's CEO, Clayton Astles, stated that the forecast first-half FY25 results demonstrate the strength of Austco Healthcare's strategy and its ability to deliver sustained growth, with the integration of Teknocorp and Amentco enhancing the company's capabilities and its core business continuing to perform strongly.

Austco Healthcare forecasts revenue of $35.8 million to $36.9 million and EBITDA of $4.5 million to $5.1 million for the first half of FY25.